PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation

Cell Death and Disease

Volumn 3, Issue 8, 2012, Pages

  Strand, D W ^a   Jiang, M ^a   Murphy, T A ^a   Yi, Y ^a   Konvinse, K C ^a   Franco, O E ^a   Wang, Y ^a   Young, J D ^a,b   Hayward, S W ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Differentiation; Fatty acid metabolism; Peroxisome proliferator activated receptor gamma (g); PPARg; Prostate

Indexed keywords

ACOT1 PROTEIN; CD36 ANTIGEN; FATTY ACID BINDING PROTEIN 4; LPL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROTEIN; PYRUVATE DEHYDROGENASE KINASE 4; SCD1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASAL CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID DESATURATION; FATTY ACID OXIDATION; GLUCOSE OXIDATION; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPOGENESIS; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DIET, HIGH-FAT; DOWN-REGULATION; EPITHELIAL CELLS; FATTY ACIDS; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; GLUCOSE; LIPOGENESIS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; OXIDATIVE STRESS; PPAR GAMMA; PROSTATE; PROTEIN ISOFORMS; STEAROYL-COA DESATURASE; THIAZOLIDINEDIONES;

MUS;

EID: 84865744185     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.99     Document Type: Article

References (40)

1. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 8: 483-494.
2. Bourke JB, Griffin JP. Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J 1968; 4: 492-493.
3. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568. (Pubitemid 44024618)
4. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006; 98: 1038-1042. (Pubitemid 44536455)
5. Burke JP, Rhodes T, Jacobson DJ, McGree ME, Roberts RO, Girman CJ et al. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 41-46. (Pubitemid 43946289)
6. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163: 1725-1729. (Pubitemid 30366722)
7. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Diff Res Biol Div 2011; 82: 244-252.
8. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL. A prospective study of the associations between treated diabetes and cancer outcomes. Diab Care 2012; 35: 113-118.
9. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010; 19: 2088-2096.
10. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 283-294.
11. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201-2207. (Pubitemid 36629867)
12. Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010; 91: 262S-266S.
13. Hsiao G, Chapman J, Ofrecio JM, Wilkes J, Resnik JL, Thapar D et al. Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 2011; 300: E164-E174.
14. He W, Barak Y, Hevener A, Olson P, Liao D, Le J et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003; 100: 15712-15717. (Pubitemid 38021055)
15. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553-2561. (Pubitemid 26187343)
16. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-618. (Pubitemid 38056345)
17. Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H et al. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 2010; 17: 469-481.
18. Jiang M, Jerome WG, Hayward SW. Autophagy in nuclear receptor PPARgamma-deficient mouse prostatic carcinogenesis. Autophagy 2010; 6: 175-176.
19. Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW. PPARgamma: A molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 2011; 82: 220-236.
20. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789. (Pubitemid 27318225)
21. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 2001; 131: 1129-1132. (Pubitemid 32275088)
22. Sampath H, Ntambi JM. The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation. Ann N Y Acad Sci 2011; 1243: 47-53.
23. Miyazaki M, Sampath H, Liu X, Flowers MT, Chu K, Dobrzyn A et al. Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice. Biochem Biophys Res Commun 2009; 380: 818-822.
24. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 2005; 115: 1699-1702. (Pubitemid 40979705)
25. Sears DD, Hsiao G, Hsiao A, Yu JG, Courtney CH, Ofrecio JM et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci USA 2009; 106: 18745-18750.
26. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007; 3: e64.
27. Walden TB, Hansen IR, Timmons JA, Cannon B, Nedergaard J. Recruited vs. nonrecruited molecular signatures of brown, "brite," and white adipose tissues. Am J Physiol Endocrinol Metab 2012; 302: E19-E31.
28. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998; 139: 4920-4927. (Pubitemid 28533438)
29. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378(9785): 31-40.
30. Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta. 2010; 1801: 252-265.
31. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570.
32. Strand DW, Franco OE, Basanta D, Anderson AR, Hayward SW. Perspectives on tissue interactions in development and disease. Curr Mol Med 2010; 10: 95-112.
33. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269-1277. (Pubitemid 32202838)
34. Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C et al. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J cancer 2005; 114: 563-571. (Pubitemid 40349614)
35. Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 2010; 9: 1740-1754.
36. Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 2010; 161: 1708-1721.
37. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010; 70: 79-89.
38. Rikimaru K, Wakabayashi T, Abe H, Imoto H, Maekawa T, Ujikawa O et al. A new class of non-thiazolidinedione, non-carboxylic-acid-based higshly selective peroxisome proliferator-activated receptor (PPAR) gamma agonists: design and synthesis of benzylpyrazole acylsulfonamides. Bioorg Med Chem 2012; 20: 714-733.
39. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
40. Glacken MW, Adema E, Sinskey AJ. Mathematical descriptions of hybridoma culture kinetics: I. Initial metabolic rates. Biotechnol Bioeng 1988; 32: 491-506.